PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2018.3242019512718-726A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahnhttp://e-crt.org/upload/pdf/crt-2018-324.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2018.324, http://www.e-crt.org/upload/pdf/crt-2018-324.pdf
Lung Cancer10.1016/j.lungcan.2015.08.0202015902261-266Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIsSu Jin Lee, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahnhttps://api.elsevier.com/content/article/PII:S0169500215300441?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0169500215300441?httpAccept=text/xml
BMC Cancer10.1186/1471-2407-12-4232012121A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancerNabil Mubarak, Rabab Gaafar, Samir Shehata, Tarek Hashem, Dani Abigeres, Hamdy A Azim, Gamal El-Husseiny, Hamed Al-Husaini, Zhixin Liuhttp://link.springer.com/content/pdf/10.1186/1471-2407-12-423.pdf, http://link.springer.com/article/10.1186/1471-2407-12-423/fulltext.html, http://link.springer.com/content/pdf/10.1186/1471-2407-12-423
Cancer Research and Treatment10.4143/crt.2014.2442015474630-637Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with <i>EGFR</i> MutationsSehhoon Park, Bhumsuk Keam, Se Hyun Kim, Ki Hwan Kim, Yu Jung Kim, Jin-Soo Kim, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heohttp://e-crt.org/upload/pdf/crt-2014-244.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.244, http://www.e-crt.org/upload/pdf/crt-2014-244.pdf
Clinical Lung Cancer10.1016/j.cllc.2011.06.0062011126402-406Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)Domenico Galetta, Salvatore Pisconti, Saverio Cinieri, Giovanni Luigi Pappagallo, Vittorio Gebbia, Nicola Borsellino, Evaristo Maiello, Antonio Rinaldi, Michele Montrone, Pietro Rizzo, Nicola Marzano, Nicola Sasso, Antonio Febbraro, Giuseppe Coluccihttps://api.elsevier.com/content/article/PII:S1525730411001513?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411001513?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdx671.035201728x137Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP studyY. Tsutani, Y. Miyata, T. Masuda, K. Fujitaka, M. Doi, Y. Awaya, S. Kuyama, S. Kitaguchi, K. Ueda, M. Okadahttps://api.elsevier.com/content/article/PII:S0923753419564201?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419564201?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_10/mdx671.035/21936958/mdx671.035.pdf
Cancer Chemotherapy and Pharmacology10.1007/s00280-018-3573-020188161043-1050Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancerToshirou Fukushima, Yuuki Wakatsuki, Takashi Kobayashi, Kei Sonehara, Kazunari Tateishi, Manabu Yamamoto, Takeshi Masubuchi, Fumiaki Yoshiike, Kazuya Hirai, Tsutomu Hachiya, Tomonobu Koizumihttp://link.springer.com/article/10.1007/s00280-018-3573-0/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-018-3573-0.pdf, http://link.springer.com/content/pdf/10.1007/s00280-018-3573-0.pdf
Value in Health10.1016/j.jval.2012.08.12112012157A411-A412PCN17 Indirect Comparison of the Efficacy of Erlotinib Versus Pemetrexed Plus Cisplatin as First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating MutationsC. Pereira, M. Sanches, J.F. Loffhttps://api.elsevier.com/content/article/PII:S1098301512029245?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301512029245?httpAccept=text/plain
OncoTargets and Therapy10.2147/ott.s1573702018Volume 112121-2129Efficacy of pemetrexed-based regimens in advanced non&ndash;small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic reviewHan Bao Hui, Lu Lu Yang, Xin Wang, Luan Di Yaohttps://www.dovepress.com/getfile.php?fileID=41492, https://www.dovepress.com/getfile.php?fileID=41492
Lung Cancer10.1016/j.lungcan.2014.07.003201486147-53Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 studyArmando Santoro, Gunnar N. Hillerdal, Gert Hoeffken, Adolfo Favaretto, Ramon Perez Carrion, Carla Visseren-Grul, Sophie Ameryckx, Karin Helsberg, Victoria Soldatenkova, Nawel Bourayou, Jens B. Sørensenhttps://api.elsevier.com/content/article/PII:S0169500214003031?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500214003031?httpAccept=text/plain